Interleukin-10 at the crossroads of immunity in TLR7-induced lupus - Summary - MDSpire

Interleukin-10 at the crossroads of immunity in TLR7-induced lupus

  • By

  • Johanna Pauline Williams

  • Anaïs Amend

  • Anna-Lena Schäfer

  • Paola Fernanda Ruiz-Aparicio

  • Antoine Nicolas Kraemer

  • Aileen Qian Luo

  • Laura Riechert

  • Lara Weber

  • Baerbel Keller

  • Rudolf Armin Manz

  • Reinhard Edmund Voll

  • Nina Chevalier

  • June 22, 2026

  • 0 min

Share

Objective:

To clarify the role of interleukin-10 (IL-10) in systemic lupus erythematosus (SLE), particularly its dual pro-inflammatory and anti-inflammatory effects.

Approach:
    Key Findings:
    • IL-10 exhibited both pro-inflammatory and anti-inflammatory effects on immune cells in the context of a TLR7-mediated lupus model.
    • Overall, IL-10 modestly limited disease progression in the murine model.
    • Blockade of IL-10R increased IL-17 levels and reduced regulatory T cell frequencies.
    • IL-10R blockade also decreased IL-10 and slightly interferon gamma (IFN-γ) expression.
    • STAT3 signaling was prominently activated in both T effector cells and regulatory T cells.
    Interpretation:

    IL-10 has a dual role in lupus, with its regulatory effects slightly outweighing its pro-inflammatory actions under the studied conditions.

    Limitations:
    • The study was conducted in a murine model, which may not fully replicate human SLE and its complexities.
    • Further research is needed to clarify the context-dependent effects of IL-10 signaling.
    Conclusion:

    Further investigation is required to understand how pro-inflammatory contexts influence IL-10 signaling and its outcomes.

Original Source(s)

Interleukin-10 at the crossroads of immunity in TLR7-induced lupus

  • by Johanna Pauline Williams, Anaïs Amend, Anna-Lena Schäfer, Paola Fernanda Ruiz-Aparicio, Antoine Nicolas Kraemer, Aileen Qian Luo, Laura Riechert, Lara Weber, Baerbel Keller, Rudolf Armin Manz, Reinhard Edmund Voll, Nina Chevalier

  • June 22, 2026

Related Content

FDA Clears Self-Administered Lupus Therapy

Once-weekly autoinjector approval was based on Phase 3 data, with safety consistent with intravenous administration.

When Bad Data Enters the Drug Pipeline

Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.

First HIV-Positive-to-HIV-Positive Lung Transplant Reported

The procedure was performed under a HOPE Act research protocol at an NYU Langone Health center the institution said is among the limited number of US transplant centers equipped and approved to perform HOPE lung transplants.